TP53-CHIP was associated with non-hematologic neoplasms [Fig. 2A; HR, 1.35; 95% CI, 1.16–1.58; P (Wald test) = 1.50 × 10−4] and nonneoplastic respiratory disease mortality [Fig. 2A; HR, 1.73; 95% CI, 1.35–2.23; P (Wald test) = 1.85 × 10−4], in addition to myeloid neoplasms [Fig. 2A; HR, 15.54; 95% CI, 9.56–25.28; P (Wald test) = 2.83 × 10−26] and lymphoid neoplasms [Fig. 2A; HR, 4.70; 95% CI, 2.31–9.56; P (Wald test) = 1.98 × 10−5]. This evidence concerns the gene TP53 and hematopoietic and lymphoid system neoplasm.